Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLISS-52; BLISS-76
- Sponsors GSK
- 15 Nov 2023 Results of post hoc pooled analysis from five trials: BLISS-76, BLISS-52, NEA, BLISS-SC, and EMBRACE presented at the ACR Convergence 2023
- 14 Nov 2022 Results of pooled analysis (N=3225; from the BLISS-52, BLISS-76, BLISS-SC and BLISS-Northeast Asia (NEA) studies) assessing Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus presented at the ACR Convergence 2022
- 13 Jun 2015 Results of 5 years presented at the 16th Annual Congress of the European League Against Rheumatism.